GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics.
Pharmacol Res
; 173: 105864, 2021 11.
Article
in English
| MEDLINE | ID: covidwho-1377431
ABSTRACT
The growing use of short-interfering RNA (siRNA)-based therapeutics for viral diseases reflects the most recent innovations in anti-viral vaccines and drugs. These drugs play crucial roles in the fight against many hitherto incurable diseases, the causes, pathophysiologies, and molecular processes of which remain unknown. Targeted liver drug delivery systems are in clinical trials. The receptor-mediated endocytosis approach involving the abundant asialoglycoprotein receptors (ASGPRs) on the surfaces of liver cells show great promise. We here review N-acetylgalactosamine (GalNAc)-siRNA conjugates that treat viral diseases such as hepatitis B infection, but we also mention that novel, native conjugate-based, targeted siRNA anti-viral drugs may also cure several life-threatening diseases such as hemorrhagic cystitis, multifocal leukoencephalopathy, and severe acute respiratory syndrome caused by coronaviruses and human herpes virus.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Acetylgalactosamine
/
Virus Diseases
/
RNA, Small Interfering
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Animals
/
Humans
Language:
English
Journal:
Pharmacol Res
Journal subject:
Pharmacology
Year:
2021
Document Type:
Article
Affiliation country:
J.phrs.2021.105864
Similar
MEDLINE
...
LILACS
LIS